OMIC SINGULAR GENOMICS SYSTEMS INC

Singular Genomics Announces Updated Presentation Time at the Inaugural Gilmartin Group Emerging Growth Company Showcase

Singular Genomics Announces Updated Presentation Time at the Inaugural Gilmartin Group Emerging Growth Company Showcase

Presentation now scheduled for 1:30 p.m. PT on Wednesday, August 31, 2022

SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced its presentation time at the Inaugural Gilmartin Group Emerging Growth Company Showcase has been updated.

The new time for the presentation is 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day as previously scheduled, Wednesday, August 31, 2022. Investors and other interested parties are invited to register and access a live webcast of the presentation by following this . Following the event, an archived webcast of the presentation will be available at under Presentations & Events.

About Singular Genomics Systems, Inc.

Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4 Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In development, the PX system leverages Singular’s proprietary sequencing technology, applying it as an in-situ readout to look at RNA and proteins in single cells and tissue. With these products, Singular Genomics’ mission is to empower researchers and clinicians to advance science and medicine.

Investor Contact

Matt Clawson

949-370-8500

Media Contact

Dan Budwick, 1AB

973-271-6085



EN
25/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SINGULAR GENOMICS SYSTEMS INC

 PRESS RELEASE

Singular Highlights Key G4X™ Launch Milestones and Showcases Groundbre...

Singular Highlights Key G4X™ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBT SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., an innovator in high-throughput spatial multiomics technologies designed to advance precision medicine, today announced key development milestones for its G4X™ Spatial Sequencer at the Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida. G4X Early Access Program Ongoing and Broader Availability on Track The G4X Early Access Program is currently underway a...

 PRESS RELEASE

Singular Genomics Announces Closing of Acquisition by Deerfield Manage...

Singular Genomics Announces Closing of Acquisition by Deerfield Management SAN DIEGO, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today the closing of its acquisition by an affiliate of Deerfield Management Company, L.P.    On December 23, 2024, Singular Genomics announced that Deerfield had signed a definitive agreement to acquire all of the outstanding shares of Singular Genomics common stock not currently...

 PRESS RELEASE

Singular Genomics Enters into Agreement to be Acquired by Deerfield fo...

Singular Genomics Enters into Agreement to be Acquired by Deerfield for $20.00 in Cash per Share SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC) (“Singular Genomics” or the “Company”), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it has entered into a definitive merger agreement whereby an affiliate of Deerfield Management Company, L.P. will acquire Singular Genomics in an all-cash transaction for $20.00 per share. The $20.00 per share...

 PRESS RELEASE

Singular Genomics Reports Recent Updates and Third Quarter 2024 Financ...

Singular Genomics Reports Recent Updates and Third Quarter 2024 Financial Results SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2024. “In the third quarter, we made significant progress in the development of the G4X spatial sequencer,” said Drew Spaventa, Chairman and Chief Executive Office...

 PRESS RELEASE

Singular Genomics Receives Non-Binding Acquisition Proposal from Conce...

Singular Genomics Receives Non-Binding Acquisition Proposal from Concentra Biosciences and Tang Capital SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today that it has received an unsolicited non-binding proposal from Concentra Biosciences, LLC (“Concentra”) to acquire all of the Company’s outstanding shares of common stock for $12.00 per share in cash. As alternative consideration, Concentra stated...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch